メタ情報
| meta description平均長 | 157 |
|---|
| OGPありページ数 | 20 |
|---|
| Twitterカードありページ数 | 0 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 54 |
|---|
| ページあたり内部リンク平均 | 31.2 |
|---|
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| personal | 1 |
| data | 0.960777 |
| Biocapital | 0.438432 |
| Newton | 0.42212 |
| ニュートン | 0.415143 |
| diseases | 0.340909 |
| treatment | 0.316637 |
| our | 0.291962 |
| sustainability | 0.26203 |
| RNA | 0.26203 |
| EP102 | 0.25 |
| you | 0.246618 |
| cell | 0.244561 |
| NBC | 0.231378 |
| バイオキャピタルは | 0.230282 |
| drug | 0.227093 |
| its | 0.220861 |
| companies | 0.219216 |
| company | 0.210082 |
| any | 0.204545 |
| Sustainability | 0.201496 |
| has | 0.201496 |
| have | 0.193853 |
| financial | 0.192155 |
| clinical | 0.183151 |
| will | 0.183151 |
| which | 0.18268 |
| processing | 0.181818 |
| your | 0.180739 |
| investment | 0.17522 |
| cancer | 0.174687 |
| patients | 0.167255 |
| METTL3 | 0.159091 |
| platform | 0.159091 |
| liver | 0.159091 |
| technology | 0.159091 |
| purposes | 0.159091 |
| protection | 0.159091 |
| お客様は | 0.159091 |
| such | 0.158319 |
| cells | 0.157218 |
| discovery | 0.157218 |
| portfolio | 0.155278 |
| first | 0.146521 |
| You | 0.139749 |
| trial | 0.139749 |
| developed | 0.139749 |
| Japan | 0.136723 |
| regional | 0.136364 |
| First | 0.136364 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| Biocapital | Newton | 4.415402 | 192 |
| data | personal | 4.132504 | 175 |
| ニュートン | バイオキャピタルは | 3.247598 | 66 |
| conditions | health | 3.016835 | 32 |
| chronic | health | 2.809041 | 28 |
| reimbursement | systems | 2.790541 | 20 |
| Council | Parliament | 2.790541 | 20 |
| Council | November | 2.790541 | 20 |
| discovery | drug | 2.626158 | 32 |
| increase | regional | 2.607105 | 15 |
| pricaf | priv | 2.606324 | 16 |
| droit | priv | 2.606324 | 16 |
| belge | droit | 2.606324 | 16 |
| Adverse | Impacts | 2.606324 | 16 |
| European | Regulation | 2.599055 | 20 |
| European | Parliament | 2.599055 | 20 |
| molecule | small | 2.599055 | 20 |
| Epics | Therapeutics | 2.585192 | 21 |
| companies | portfolio | 2.536866 | 46 |
| SUBMIT | YOUR | 2.535289 | 19 |
| sector | services | 2.523062 | 20 |
| insulin | resistance | 2.492879 | 16 |
| disclosures | related | 2.456032 | 20 |
| create | value | 2.419303 | 20 |
| Europe | Japan | 2.413076 | 24 |
| ischemic | stroke | 2.400187 | 16 |
| DATA | PERSONAL | 2.400187 | 16 |
| diabetes | type | 2.379434 | 16 |
| scene | setting | 2.369626 | 12 |
| Environmental | Social | 2.369626 | 12 |
| Corporate | Social | 2.369626 | 12 |
| Corporate | Governance | 2.369626 | 12 |
| contributed | substantial | 2.369626 | 12 |
| off | spin | 2.369626 | 12 |
| disclosures | financial | 2.341831 | 20 |
| financial | services | 2.341831 | 20 |
| com | newtonbiocapital | 2.34138 | 12 |
| decision | making | 2.321818 | 16 |
| First | Patient | 2.321818 | 16 |
| Regulation | SFDR | 2.286743 | 16 |
| decisions | investment | 2.272642 | 29 |
| Parliament | Regulation | 2.27012 | 15 |
| November | Parliament | 2.27012 | 15 |
| disclosures | services | 2.27012 | 15 |
| business | proposal | 2.259789 | 17 |
| Notice | Privacy | 2.2532 | 10 |
| Adverse | Principle | 2.243718 | 12 |
| grounds | legitimate | 2.243718 | 12 |
| Muromachi | Nihonbashi | 2.223668 | 9 |
| period | retention | 2.223668 | 9 |